LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
STRR
Star Equity Holdings, Inc.
There isn't enough reported data to score STRR yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
STRR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
STRR's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
STRR PE Valuation
STRR has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
STRR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for STRR, with profitability improving. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over STRR on earnings quality, reporting a profit while its opponent remains loss making.
STRR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.50 | — |
| Q3 2026 | -$2.43 | -$0.86 |
| Q2 2026 | -$2.54 | -$1.23 |
| Q1 2026 | -$2.27 | -$1.04 |
| Q4 2025 | -$1.85 | -$0.26 |
| Q3 2025 | -$1.57 | -$0.43 |
| Q2 2025 | -$1.31 | -$0.62 |
| Q1 2025 | -$1.23 | -$0.87 |
| Q4 2024 | -$1.59 | -327% |
STRR lost $2.43 per share over the past year, a bigger loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over STRR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over STRR on profitability, with a higher operating margin.
STRR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $53.9M | +12% |
| Q2 2026 | $54.9M | +55% |
| Q1 2026 | $50.1M | +57% |
| Q4 2025 | $56.8M | +69% |
| Q3 2025 | $48M | +30% |
| Q2 2025 | $35.5M | -0.5% |
| Q1 2025 | $31.9M | -6% |
| Q4 2024 | $33.6M | -1.1% |
STRR's revenue has grown year over year for five quarters in a row: $54M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.4% | +0.1 points |
| Q2 2026 | -2.5% | -1.9 points |
| Q1 2026 | -8% | -2.6 points |
| Q4 2025 | -0.2% | +0.2 points |
| Q3 2025 | -3.4% | -2.2 points |
| Q2 2025 | -0.6% | -0.1 points |
| Q1 2025 | -5.4% | +3.6 points |
| Q4 2024 | -0.4% | +3.4 points |
STRR's operating margin was −3.4% last quarter, about level with the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over STRR on cash generation, producing positive trailing cash flow while its opponent burns cash.
STRR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $60K | +$3.4M |
| Q2 2026 | -$3.2M | -3269% |
| Q1 2026 | -$2.7M | -$1.9M |
| Q4 2025 | -$4.9M | -342% |
| Q3 2025 | -$3.4M | -368% |
| Q2 2025 | $102K | +$4.4M |
| Q1 2025 | -$808K | +$986K |
| Q4 2024 | $2M | -39% |
STRR's free cash flow was −$11M over the past year, against −$2M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over STRR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
STRR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -3K shares |
| 1 year | +13% | +438K shares |
| 3 years | +18% | +560K shares |
| 5 years | +22% | +679K shares |
| Available history | +18% | +570K shares |
STRR has 4M diluted shares, up 13% from a year ago, despite $1M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $306,000 |
| Q2 2026 | $157,000 |
| Q1 2026 | $712,000 |
| Q4 2025 | $66,000 |
| Q3 2025 | $2.6M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
STRR spent $1M buying back its own shares over the past year, down 52% from the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
STRR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -7.9x | Net Cash |
| Q3 2023 | -4.6x | Net Cash |
| Q2 2023 | -4.9x | Net Cash |
| Q1 2023 | -2.9x | Net Cash |
| Q4 2022 | -2.4x | Net Cash |
| Q3 2022 | -1.7x | Net Cash |
| Q2 2022 | -1.9x | Net Cash |
| Q1 2022 | -2.0x | Net Cash |
STRR has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
STRR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.3 | Neutral |
| Stochastic | 26.2 | Neutral |
STRR's weekly RSI is 48 (neutral) and its Stochastic is 26 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
STRR PE vs Healthcare Sector
| Metric | STRR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
STRR has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over STRR on trend strength, trading above more of its moving averages.
STRR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.84 | 1.6% above |
| 20 week MA | $10.3 | 2.9% below |
| 50 week MA | $10.3 | 3.1% below |
| 100 week MA | $10.4 | 3.6% below |
| 200 week MA | $14.2 | 30% below |
STRR has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 30% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over STRR on returns for 2026, with the stronger performance.
STRR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.5 | $10.7 | -14% |
| 2021 | $10.7 | $27.4 | +155% |
| 2022 | $27.4 | $23.5 | -14% |
| 2023 | $23.5 | $15.5 | -34% |
| 2024 | $15.5 | $13.4 | -14% |
| 2025 | $13.4 | $10.9 | -18% |
| 2026 YTD | $10.9 | $10.0 | -8.4% |
STRR has finished four years in a row lower, and it's down 8.4% so far in 2026.